相关实验视频

Updated: May 11, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

对患有细胞癌的患者提供基于生物标志物的护理

Mackenzie B McKinnon¹, Brian I Rini^1,2, Scott M Haake^3,4,5

¹Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

|April 16, 2025

概括

预测免疫检查点抑制剂反应的生物标志物对于清细胞细胞癌 (ccRCC) 是必要的. 这项研究审查了现有的生物标志物和新兴策略,如ccRCC治疗的基因表达特征.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因组学就是基因组学.

背景情况:

清细胞细胞癌 (ccRCC) 是最常见的癌亚型.
免疫检查点抑制剂 (ICI) 改善了ccRCC治疗结果.
目前,在ccRCC中缺乏ICI治疗的预测生物标志物.

研究的目的:

探索用于其他癌症的生物标志物,可以预测对ICI的反应.
了解为什么这些生物标志物在ccRCC中无效.
识别和优先考虑ccRCC的新兴生物标志物,包括基因表达特征.

主要方法:

在各种瘤类型中对ICI反应的生物标志物的文献综述.
在ccRCC中分析生物标志物无效的原因.
对ccRCC新兴预测和预后生物标志物的审查.

主要成果:

在其他癌症中有效的生物标志物通常在ccRCC中由于瘤特异性生物学而失败.
基因表达特征在ccRCC中显示出有前途的预测生物标志物.
需要进一步的研究来验证新的生物标志物.

结论:

对于经过验证的生物标志物来指导ccRCC中的ICI疗法是非常需要的.
新出现的生物标志物,特别是基因表达特征,需要进一步研究.
可靠的预测标记可以增强ccRCC的个性化治疗策略.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...